Vernalis completes the acquisition of Cita NeuroPharmaceuticals Inc
Vernalis plc announced that it has completed the acquisition of the privately held Canadian company, Cita NeuroPharmaceuticals Inc.
In consideration for Vernalis acquiring the entire issued share capital of Cita, Vernalis has issued as initial consideration 26,915,831 new Vernalis Ordinary Shares. Of these shares, 2,630,847 Ordinary Shares have been issued to certain Cita shareholders and the remaining 24,284,984 Ordinary Shares have been placed by Piper Jaffray pursuant to a Vendor Placing, which also completed today, to realise cash proceeds payable to certain Cita shareholders of £15.3 million (before expenses).
As a result of the acquisition of Cita (including the Vendor Placing) and a Placing and Open Offer by the Company, which also completed today, the enlarged issued share capital of Vernalis is 311,463,549 Ordinary Shares.
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.